The study, published in the Journal of Neuro-Oncology, tackles a problem that has grown more pressing as whole-brain radiation therapy has fallen out of favor. Brain metastases, the spread of cancer to the brain from tumors elsewhere in the body, are estimated to occur in a substantial fraction of patients with advanced cancer, and as systemic therapies extend survival, more patients live long enough to face complications in the brain itself. Modern guidelines from ASTRO, ASCO, and the Society for Neuro-Oncology favor stereotactic radiosurgery, which concentrates high radiation doses on individual tumors while sparing healthy tissue. But large lesions, defined in this study as those with a volume of at least 4 cubic centimeters, pose a special challenge. A single massive dose of radiation risks injuring surrounding brain tissue, so clinicians must choose between single-session treatment, splitting the dose into staged sessions weeks apart, or delivering it in a handful of larger-than-conventional fractions known as hypofractionation. Which strategy works best, and at what dose, has remained genuinely uncertain.

The research team, led by Yuta Koketsu and corresponding author Toshinori Hasegawa, took advantage of a decade of experience at a single Gamma Knife center. Between 2016 and 2024, they treated patients with large brain metastases using all three approaches, individualizing both the treatment schedule and the radiation dose to each patient’s anatomy and clinical situation. For the analysis, they focused on one dominant lesion per patient and tracked it with serial imaging. Radiographic progression was defined conservatively as an increase of at least 20 percent in the longest tumor diameter from its smallest recorded size, the nadir. But the investigators went a crucial step further than most radiographic studies. They distinguished true progression, meaning enlargement that persisted or forced the team to intervene with additional treatment, from pseudoprogression, in which a lesion that initially appeared to grow later stabilized or shrank on its own without any salvage therapy. This distinction matters enormously, because treating pseudoprogression with more radiation or surgery exposes patients to harm for a problem that would have resolved by itself.

The headline result concerns dose. Using the concept of biologically effective dose, a radiobiological formula that converts different dose-and-fractionation schedules into a single number reflecting the expected biological effect on tumor cells, the team found a clear threshold. Lesions that received a BED10 of at least 57.6 Gy had a significantly lower risk of true progression, with a subdistribution hazard ratio of 0.46, meaning the hazard was cut by more than half, and the difference was statistically significant at p equals 0.02. In practical terms, the BED10 framework rewards clinicians for thinking beyond the raw dose number on a treatment plan. A modest dose delivered in a single session and a larger total dose spread over several sessions can be biologically equivalent to tumor cells, and the 57.6 Gy threshold gives clinicians a common currency for comparing schedules. Notably, the analysis found that true progression rates did not differ significantly by treatment modality, whether single-session, staged, or hypofractionated, or by tumor volume, suggesting that what matters is the total biological punch delivered rather than the specific way it is packaged.

The cumulative incidence figures tell the story of what patients face over time. At six months after Gamma Knife surgery, 17.4 percent of lesions had undergone true progression. By twelve months, that figure had climbed to 31.5 percent, and by twenty-four months it had essentially plateaued at 33.1 percent. That plateau is clinically meaningful: it suggests that if a large treated metastasis is going to truly regrow, it almost always does so within the first year, and a patient who reaches the two-year mark with local control is unlikely to lose it. The median overall survival of the entire cohort was 15.3 months, which means that for a large share of these patients, the question of local tumor control is not academic; it unfolds within their actual lifespan and directly affects their quality of life and neurological function.

Of the 143 lesions followed, 47 eventually showed radiographic progression, but the breakdown reveals how treacherous imaging interpretation can be. Forty-two turned out to be true progression, four were pseudoprogression, and one was attributed to intratumoral hemorrhage. In other words, roughly one in ten radiographic failures was not a failure at all. The pseudoprogression phenomenon reflects radiation necrosis, a delayed injury to brain tissue in and around the treated lesion that can cause the enhancing area on MRI to enlarge, mimic tumor growth, produce mass effect and edema, and even bring back a patient’s original neurological symptoms. Biopsy series from other centers have repeatedly shown that enlarging lesions after radiosurgery frequently contain necrosis rather than viable tumor. The Komaki team illustrated the point vividly in a supplementary case: a man in his seventies with a 66 cubic centimeter occipital metastasis causing hemianopsia and Gerstmann syndrome received two-stage Gamma Knife treatment with 12 Gy per stage. His symptoms resolved and the tumor shrank dramatically, but a year later the lesion enlarged again with worsening edema and recurrent vision loss, apparently demanding salvage therapy. Instead, it stabilized on its own at eighteen months and the edema improved by twenty-two months, consistent with radiation necrosis running its natural course.

How, then, can clinicians tell the impostor from the real thing? The study’s most actionable finding is a timing signature. Recurrent peritumoral edema, the reappearance or worsening of fluid accumulation in brain tissue around the lesion, developed far earlier in true progression than in pseudoprogression, with a median of 173.5 days versus 564 days, a difference that was highly significant at p equals 0.001. When tumor enlargement and renewed edema arrive together within roughly the first year after treatment, the pattern strongly indicates genuine tumor regrowth, and the authors conclude that such a finding should prompt consideration of early salvage intervention rather than a prolonged wait-and-see approach. Conversely, enlargement with edema emerging well beyond the one-year mark is more consistent with late radiation necrosis, where observation may spare the patient unnecessary surgery or reirradiation. This simple temporal rule requires no advanced imaging, no perfusion sequences, no spectroscopy, and no biopsy, only careful attention to the calendar alongside the MRI.

The study also speaks to what happens when a lesion does fail and clinicians reach for a second round of Gamma Knife treatment. Among patients who underwent repeat radiosurgery, a lower marginal dose at the second session was associated with subsequent true progression, with a hazard ratio of 0.82 per dose increment, significant at p equals 0.02. The interpretation is sobering: underdosing at salvage treatment appears to invite another failure, yet pushing the dose higher raises the specter of radiation necrosis, particularly since the surrounding tissue has already been irradiated. Repeat stereotactic radiosurgery for recurrent brain metastases is well established in the literature, with systematic reviews and meta-analyses documenting both its efficacy and its necrosis risk, and the new data add a quantitative argument for dosing salvage sessions deliberately rather than timidly. The team notes that their institution has also explored combined approaches, including reirradiation followed by resection, for select recurrent lesions.

Why does dose matter so much biologically? The answer lies in classic radiation biology. Tumor cells vary in their oxygenation, and cells at intermediate oxygen levels can substantially influence the response of a tumor to fractionated radiotherapy, a relationship explored in foundational work by Wouters and Brown. Hypoxic cells require more radiation to kill, and fractionation schedules that allow tumor reoxygenation between sessions can partially compensate, which is precisely why the BED10 framework, which encodes the effect of fractionation, is a better predictor of control than the physical dose alone. Large metastases are also more likely than small ones to contain poorly oxygenated cores and to press against eloquent brain structures that force dose reductions, creating a tension between tumor control and toxicity that the 57.6 Gy threshold helps clinicians navigate quantitatively.

The study’s limitations are those inherent to its design: it was retrospective, conducted at a single institution, and treatment decisions were individualized rather than randomized, so selection biases cannot be fully excluded. Datasets are available from the corresponding author on reasonable request, and the work received no specific external funding. Still, the practical takeaways are hard to ignore. For patients with large brain metastases, the total biologically effective dose delivered to the tumor edge should be planned to reach at least 57.6 Gy BED10, using whatever fractionation scheme best protects the surrounding brain. And in follow-up, the pairing of tumor enlargement with recurrent peritumoral edema within a year of Gamma Knife surgery should be read not as an ambiguous radiological curiosity but as a call to act, because in this disease, waiting for certainty can cost patients the window in which salvage treatment works best.

Subject of Research: Dose selection and progression assessment after Gamma Knife radiosurgery for large brain metastases

Article Title: Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression

Article References: Koketsu, Y., Hasegawa, T., Kato, T., Naito, T., Mizuno, A., Ando, Y., Kosaka, N., & Saito, R. (2026). Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression. Journal of Neuro-Oncology, 180(1), Article 3. https://doi.org/10.1007/s11060-026-05792-0

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05792-0

Keywords: Gamma Knife surgery, stereotactic radiosurgery, brain metastases, biologically effective dose, pseudoprogression, radiation necrosis, peritumoral edema, salvage therapy, hypofractionation, tumor progression, radiation oncology, neuro-oncology

The research team, led by Jinhui Li, Feilin Qu, Xiaohui Zhu, and senior authors including Weijun Peng, Chao You, and Zhiming Shao, set out to address a deceptively simple question: can the cellular neighborhoods inside a recurrent breast tumor be linked to features that radiologists can already see on a scan? If so, the routinely acquired MRI might serve as a noninvasive window into the biology of metastatic risk, sparing patients from invasive sampling while flagging those who need intensified surveillance or adjuvant therapy. The study is explicitly exploratory, and the authors are careful to frame their findings as hypothesis-generating rather than clinically actionable, but the approach itself represents a growing trend in cancer research: the fusion of spatially resolved molecular data with clinical imaging phenotypes, a field often described as radiogenomics.

To build their spatial atlas, the investigators used the CosMx Spatial Molecular Imager, a platform capable of profiling gene expression across intact tissue sections while preserving the physical locations of individual cells. This matters because conventional single-cell sequencing, however powerful, requires dissociating tissue into a suspension, which destroys the spatial relationships that many biologists now consider essential to understanding tumor behavior. The study included 21 patients with ipsilateral breast tumor recurrence, of whom 8 had developed distant metastasis during follow-up while 13 remained metastasis-free. This metastatic versus non-metastatic comparison formed the biological backbone of the analysis. Among the full cohort, 9 patients had preoperative contrast-enhanced MRI scans available, enabling the imaging-to-molecular correlation that gives the study its distinctive character.

The spatial profiling revealed the expected cast of characters within the recurrent tumor microenvironment: diverse immune cell populations, malignant epithelial cells, stromal cells, and endothelial cells lining the vasculature. But the differences between metastatic and non-metastatic cases were what captured the team’s attention. Tumors from patients who later developed distant metastasis showed enrichment of particular subtypes of cancer-associated fibroblasts, the stromal cells that remodel the tissue matrix and are increasingly recognized as active accomplices in tumor progression rather than passive scaffolding. Specific immune cell populations were also enriched in the metastatic group, hinting that the immune landscape of a recurrence may encode information about its future behavior.

Using a computational approach based on latent Dirichlet allocation, a statistical method originally developed for text analysis that can identify recurring themes, the researchers decomposed the tissue into nine distinct multicellular spatial niches, each representing a characteristic mixture of cell types occupying a shared microanatomical neighborhood. One of these, Niche 1, stood out. It was more abundant in metastatic cases and was defined by the close co-enrichment of three cell types with a well-documented history of collaboration in cancer biology: epithelial tumor cells, cancer-associated fibroblasts, and tumor-associated macrophages. This triad has been implicated in tumor progression across many cancer types, and its spatial consolidation into a single niche within metastasis-prone recurrences suggests a structural basis for aggressive behavior.

To probe what these cells might be saying to one another, the team applied CellChat, a computational framework that infers putative ligand-receptor signaling interactions from co-expressed gene pairs in adjacent cell populations. Within Niche 1, the analysis pointed to interactions between the stromal and epithelial compartments mediated by collagen signaling, specifically the COL1A1 ligand engaging the SDC1 and CD44 receptors on epithelial cells. Collagen I is a major structural component of the extracellular matrix, and its receptors are known to influence cell adhesion, migration, and survival. The inference that fibroblast-derived collagen may be communicating directly with tumor cells through these pathways is consistent with a body of literature linking matrix remodeling to invasion and dissemination, though the authors emphasize that these are computationally inferred interactions that require experimental validation.

The most provocative part of the study lies in its attempt to connect this molecular cartography to what radiologists actually observe. Among the nine patients with available MRI, the team assessed several qualitative imaging phenotypes: background parenchymal enhancement, or BPE, which reflects how much contrast agent the normal breast tissue takes up; lesion type; multifocality, the presence of multiple tumor foci; and peritumoral edema, fluid accumulation visible around the tumor. Strikingly, high BPE and the presence of peritumoral edema were both associated with a higher abundance of Niche 1 and its constituent cellular components. In other words, a feature visible on a routine clinical scan appeared to track with the presence of a metastasis-associated cellular neighborhood inside the tumor.

Gene set enrichment analysis added a further layer of biological texture to the imaging correlations. Tumors from patients with high BPE showed enrichment of the interferon-alpha and interferon-beta signaling pathways, suggesting that the bright background enhancement on MRI may correspond to an inflamed, interferon-active microenvironment. Conversely, epithelial-mesenchymal transition signatures, a gene expression program associated with cells acquiring migratory and invasive properties, were observed in the low-BPE, mass-enhancement, and no-edema subgroups. The implication is that different MRI phenotypes may be capturing fundamentally different biological programs rather than simply grading the same underlying process on a continuum. A radiologist’s qualitative description of a breast MRI may therefore carry more molecular information than the field has traditionally appreciated.

The authors are appropriately measured in their conclusions. With 21 patients in the spatial cohort and only 9 in the imaging-linked subset, the statistical power of these associations is limited, and the retrospective design introduces the usual caveats about selection and confounding. The study was conducted in accordance with the Declaration of Helsinki with approval from the Institutional Review Board of Fudan University Shanghai Cancer Center, and it was supported by funding from the National Natural Science Foundation of China and several Shanghai municipal research programs. The team states plainly that the observed associations between BPE, peritumoral edema, and metastasis-associated spatial niches generate hypotheses for future radiogenomic studies but require validation in larger, independent cohorts before any clinical application can be contemplated.

Even so, the conceptual contribution is considerable. The work demonstrates a practical pipeline for fusing spatial transcriptomics with qualitative MRI phenotyping, showing that the two modalities can be bridged in a way that yields biologically interpretable results. If the findings hold up in larger studies, the long-term vision is compelling: a routine contrast-enhanced MRI that not only detects a recurrence but also reads out, noninvasively, the cellular neighborhoods brewing within it, identifying patients whose tumors harbor the fibroblast-macrophage-epithelial ensembles associated with metastatic spread. Such a capability would sharpen decisions about surveillance intensity, systemic therapy, and the design of clinical trials for patients with recurrent breast cancer. For now, the study stands as an early but instructive demonstration that the radiologist’s image and the biologist’s tissue map can, quite literally, be brought into the same frame.

Subject of Research: Integration of spatial transcriptomics and MRI phenotyping to characterize the metastasis-associated tumor microenvironment in ipsilateral breast tumor recurrence

Article Title: Exploratory integration of spatial transcriptomics and MRI phenotypes to characterize metastasis-associated microenvironmental features in ipsilateral breast tumor recurrence

Article References: Li, J., Qu, F., Zhu, X., Li, J., Shao, Z., You, C., & Peng, W. (2026). Exploratory integration of spatial transcriptomics and MRI phenotypes to characterize metastasis-associated microenvironmental features in ipsilateral breast tumor recurrence. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08855-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08855-y

Keywords: breast cancer, ipsilateral breast tumor recurrence, spatial transcriptomics, tumor microenvironment, MRI, background parenchymal enhancement, cancer-associated fibroblasts, tumor-associated macrophages, metastasis, radiogenomics, CellChat, peritumoral edema